The clinical trial will measure several efficacy endpoints including time to amputation, transcutaneous oximetry (TcPO2), Ankle-Brachial Index (ABI) and ulcer closure.
Juventas said that JVS-100 encodes Stromal-cell Derived Factor 1 (SDF-1), which has been shown in several pre-clinical studies to promote tissue repair through activation of natural stem-cell repair pathways, promotion of new blood vessel formation and prevention of on-going cell death.
Juventas president and CEO Rahul Aras said that Juventas is excited to extend its clinical pipeline to include treatment of patients with CLI.
Juventas chief medical officer Marc Penn said that they believed that if they could identify the molecular factors that activate this pathway, they could be delivered at a time post-injury to promote tissue preservation.